The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to VER-01, an investigational, non-opioid treatment for chronic low back pain developed by Vertanical. The designation is reserved for therapies that show substantial improvement over existing treatments and allows for an accelerated development and review pathway in the United States.
Chronic low back pain is one of the leading causes of disability worldwide, with limited long-term treatment options outside opioids, antidepressants, and invasive procedures. Against the backdrop of the opioid crisis, the need for effective non-opioid alternatives has become urgent. VER-01 is positioned as a potential first-in-class therapy designed to meet that need.
Phase 3 Data Show Significant Pain Reduction
According to clinical trial results, VER-01 demonstrated statistically significant reductions in pain intensity compared to placebo in large, randomized Phase 3 studies. Patients treated with the drug reported improvements not only in pain scores but also in sleep quality and physical function.
In head-to-head comparisons with opioid treatments, the cannabis-based therapy showed superior pain reduction alongside a more favorable tolerability profile. Importantly, clinical data did not indicate signals of dependency, misuse, or withdrawal symptoms — a critical distinction in chronic pain management.
The therapy is based on a standardized, pharmaceutical-grade cannabis extract with precisely defined ratios of cannabinoids and other plant constituents. Unlike many medical cannabis products on the market, VER-01 has been developed under strict regulatory standards comparable to conventional prescription medicines.
Get the week’s important news from Cannabis.se in your inbox — interesting weekend reading! 🥦✉️
Fast-Tracked in the U.S., Advancing in Europe
Breakthrough Therapy Designation from the FDA provides closer guidance from the agency and the possibility of priority review once a New Drug Application is submitted. An additional pivotal Phase 3 study is planned in the United States, with regulatory submission targeted later in the decade if results remain positive.
In Europe, regulatory momentum is also building. Germany is expected to be among the first markets where approval could be granted, reflecting the country’s structured framework for medical cannabis and prescription medicines. Several other European countries are reportedly preparing for potential authorization, which would mark one of the first full approvals of a cannabis-derived therapy for chronic pain under pharmaceutical standards.
A Full-Spectrum Extract — Framed as a Modern Pharmaceutical
At its core, VER-01 is a full-spectrum cannabis extract. It contains multiple cannabinoids and terpenes that may act synergistically — a concept often described as the entourage effect. This distinguishes it from single-molecule cannabinoid drugs.
At the same time, the company clearly aims to position the product as more than “just cannabis.” By emphasizing standardization, reproducibility, and rigorous Phase 3 clinical validation, the therapy is being framed as a modern, evidence-based pharmaceutical product rather than a traditional plant-based remedy.
The coming years will determine whether regulators in the United States and Europe fully embrace this approach. If approved, VER-01 could represent a milestone in the transformation of cannabis from botanical medicine to mainstream prescription drug.
Sponsor: Sensi Seeds are one of Europe’s most recognized names in premium cannabis genetics, offering a wide selection of feminized, autoflowering, CBD-rich and F1 hybrid seeds for customers who want quality, consistency and choice.